Protara Therapeutics, Inc.

Protara Therapeutics, Inc. announced it will host a virtual webinar for the investment community on Tuesday, May 19, 2026, at 4:30 pm ET. The event will provide an overview of Lymphatic Malformations (LMs), the current treatment landscape, and the TARA-002 clinical program. It will also feature key opinion leader perspectives, discuss the market opportunity and regulatory path for TARA-002, and review supporting clinical data. TARA-002 holds multiple FDA designations, including Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy, and Fast Track for LMs.

Protara Therapeutics announced positive updated 12-month data from Cohort A of its Phase 2 ADVANCED-2 trial for TARA-002 in BCG-Naïve non-muscle invasive bladder cancer (NMIBC) patients. The trial demonstrated a 72% complete response (CR) rate at any time, with 67% at 6 months and 55% at 12 months. TARA-002 also showed a favorable safety profile with no Grade 3 or greater treatment-related adverse events. The company plans to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in the second half of 2026.

Protara Therapeutics reported a net loss of $17.78 million for the first quarter of 2026, an increase from $11.91 million in the same period last year, driven by higher research and development expenses. Despite the increased cash burn, the company stated it has sufficient financial resources to meet its liquidity needs for at least the next 12 months. Additionally, a significant clinical trial milestone was achieved, fixing the exercise termination date for certain common warrants.

Protara Therapeutics announced its first quarter 2026 financial results, reporting a net loss of $17.8 million, or $0.31 per share, an increase from the prior year. The company provided a business update, highlighting its intent to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in the second half of 2027. Protara also reported approximately $177 million in cash, cash equivalents, and investments as of March 31, 2026, which is expected to fund operations into 2028, and provided updates on its TARA-002 NMIBC and IV Choline Chloride programs.

Protara Therapeutics, Inc. (TARA) announced its 2026 Annual Meeting of Stockholders, to be held virtually on June 12, 2026. Key proposals include the election of three Class III directors, ratification of Ernst & Young LLP as auditor, and advisory votes on executive compensation and its frequency. The company also seeks approval for an amendment to its 2024 Equity Incentive Plan, an increase in authorized common stock from 100 million to 200 million shares, and an amendment allowing officer exculpation.